It's possible they may be looking at licensing different jurisdictions for 2591 ie North America, Europe and Asia keeping in mind they don't want split the indications, but what becomes of Neuren after that? A holding company with no more tricks up its sleeve, or it develops trofinetide for other indications when 2591 is the superior of the two drugs? I think Gerry's answer was a broad one and meant to entail takeovers also. Surely the company is more valuable being sold in its entirety given the royalties and milestone payments from trofinetide is significant.
NEU Price at posting:
$12.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)